Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle
Top Cited Papers
- 10 February 2004
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 6 (4) , 395-404
- https://doi.org/10.1002/jgm.516
Abstract
Background Although the transient nature of transgene expression using first‐generation adenovirus (Ad) vectors is well known, the exact mechanisms responsible for this phenomenon are uncertain. Methods Rats were given intramuscular (i.m.) injections of a first‐generation Ad containing the human fibroblast growth factor 4 (hFGF‐4) gene driven by the cytomegalovirus (CMV) promoter and enhancer (CMV‐PE). The copy number of hFGF‐4 mRNA and viral DNA was measured in the same muscles by quantitative RT‐PCR and quantitative PCR at times between 1 h and 84 days after virus injection. Quantitative Southern blot analysis for the intact hFGF‐4 transcription unit DNA was also performed, and the methylation status of the CMV‐PE DNA in the muscle was determined using bisulfite sequencing. Results The copy number of hFGF‐4 mRNA peaked at 6 h then decreased 56‐fold by 24 h, and a further 240‐fold between days 3 and 28. Although the viral DNA copy number also decreased 23‐fold between 6 h and 28 days, the ratio of copies of hFGF‐4 mRNA per copy of viral DNA decreased 385‐fold over this period. Methylation of the CMV‐PE DNA in the muscle at both CpG and non‐CpG sites was observed 24 h after virus administration and had increased at day 7. Conclusions Decreased transcription associated with extensive methylation of the CMV‐PE was the major mechanism responsible for the decrease in transgene mRNA levels. Strategies for preventing transcriptional silencing will be valuable for improving the duration of transgene expression from adenoviral vectors. Copyright © 2004 John Wiley & Sons, Ltd.Keywords
This publication has 26 references indexed in Scilit:
- Transcriptionally active drugs improve adenovirus vector performance in vitro and in vivoGene Therapy, 2000
- DNA methylation in health and diseaseNature Reviews Genetics, 2000
- DNA from Both High-Capacity and First-Generation Adenoviral Vectors Remains Intact in Skeletal MuscleHuman Gene Therapy, 1999
- New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent AdenovirusesHuman Gene Therapy, 1998
- Promoter Attenuation in Gene Therapy: Interferon-γand Tumor Necrosis Factor-αInhibit Transgene ExpressionHuman Gene Therapy, 1997
- Asymmetric Methylation in the Hypermethylated CpG Promoter Region of the Human L1 RetrotransposonJournal of Biological Chemistry, 1997
- Immunology of gene therapy with adenoviral vectors in mouse skeletal muscleHuman Molecular Genetics, 1996
- Inactivation of the Very Strong HCMV Immediate Early Promoter by DNA CpG MethylationIn VitroBiological Chemistry Hoppe-Seyler, 1996
- FK506 Immunosuppression to Control the Immune Reactions Triggered by First-Generation Adenovirus-Mediated Gene TransferHuman Gene Therapy, 1995
- DNA methylation: eukaryotic defense against the transcription of foreign genes?Microbial Pathogenesis, 1992